Raremark, the online patient community in rare disease, has launched its patient-powered knowledge platform Xperiome aiming to help the pharmaceutical industry deliver innovative new therapies faster and smarter.
The Xperiome platform expands on Raremark’s vision of a world in which all rare diseases are treated by connecting everyone affected by rare diseases through shared, lived experiences, regardless of diagnosis, while providing customized patient journeys specific to their disease indication.
Harnessing Raremark’s over 11,000 active patients and caregivers, Xperiome brings together those affected by rare conditions such as idiopathic pulmonary fibrosis, myasthenia gravis, and urea cycle disorder. By using the Xperiome platform, pharmaceutical companies can recruit and retain hard-to-reach patients in research studies, improve go-to-market strategies, and evaluate the effectiveness of new treatments in a real-world setting.
“The missing puzzle piece is often the patient perspective, especially in rare disease, where patients are so much harder to find,” said Alex Garner, Chief Operations Officer. “The Xperiome platform enables pharmaceutical companies and contract research organizations to connect with these hard-to-reach communities and uncover key insights that make the drug development process smarter.”
The Xperiome platform has been created using Raremark’s deep domain expertise in drug development, machine learning, and behavioral science. It is a growing knowledge base of patient experiences built by people affected by rare diseases, which provides a 360 degree view of rare patient journeys and allows community members to share patient-orientated guidance to researchers based on their real-world lived experiences.
Pharma companies can leverage the Xperiome platform throughout drug development and commercialization to connect with the right patients at the right time, complete missing datasets and unlock real-world insights.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.